Immix Biopharma is a clinical-stage biopharmaceutical company engaged in the development of a class of Tissue-Specific Therapeutics (TSTx) in oncology and inflammation. Co.'s primary asset, IMX-110, is for the treatment of solid tumors. IMX-110 is a negatively-charged TSTx that simultaneously disables resistance pathways with a poly-kinase inhibitor and induces tumor cell death with an apoptosis inducer, utilizing Co.'s TME Normalization Technology, delivered deep into the tumor micro-environment (TME). Co.'s TME Normalization Technology allows its drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. The IMMX average annual return since 2021 is shown above.
The Average Annual Return on the IMMX average annual return since 2021 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether IMMX average annual return since 2021 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the IMMX average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|